



569-A392

Method to enhance factor VIII production

Invention

Factor VIII is an essential blood clotting factor, mutations of which lead to hemophilia A. Several drugs based on recombinant factor VIII are currently marketed, resulting in annual sales of over \$ 3 billion.

Researchers at the University of Geneva, University Hospitals of Geneva, and University Hospital of Lausanne have jointly developed a method to enhance *in vitro* secretion of factor VIII. The method involves reducing expression of another cellular protein with which the researchers have found factor VIII to interact.

Applications

Recombinant production of factor VIII for treatment of haemophilia.

The method is specific for production of recombinant full-length factor VIII but should be compatible with most mammalian expression systems that are currently used for this purpose.

Advantages

→ Reduction of manufacturing costs for production of factor VIII

Status

Priority application 61/433,295 filed on 17.01.2011



Université de Genève
24, Rue Général-Dufour
1211 Geneva 4
Switzerland

Contact:

Raluca Flükiger, Ph.D.
Phone: +41(22)379 03 53
E-mail: raluca.flukiger@unige.ch

